Key result
Aspirin shows no benefit over heparin/warfarin for preventing 2-year post-Fontan thrombosis.
Why the study?
Thrombosis is an important complication after Fontan surgery in children with single-ventricle physiology, and the optimal primary thromboprophylaxis strategy had not been determined.
Does acetylsalicylic acid compared with heparin/warfarin reduce the risk of intracardiac or embolic thrombosis in children undergoing the Fontan procedure?
RCT (n=111)
Randomized
Yes
Does acetylsalicylic acid compared with heparin/warfarin reduce the risk of intracardiac or embolic thrombosis in children undergoing the Fontan procedure?
Acetylsalicylic acid and heparin/warfarin showed no significant difference in preventing thrombosis in the first 2 years after the Fontan procedure, though thrombosis rates were suboptimal in both groups.
Answers are grounded in this paper and cite their sources.
Informs post-Fontan antithrombotic choice in children; leaves open optimal regimen for 2-year thromboprophylaxis.
Objectives The purpose of this study was to compare the safety and efficacy of acetylsalicylic acid (ASA) and warfarin for thromboprophylaxis after the Fontan procedure. Background Fontan surgery is the definitive palliation for children with single-ventricle physiology. Thrombosis is an important complication; the optimal thromboprophylaxis strategy has not been determined. Methods We performed a multicenter international randomized trial of primary prophylactic anticoagulation after Fontan surgery. Patients were randomized to receive for 2 years either ASA (5 mg/kg/day, no heparin phase) or warfarin (started within 24 h of heparin lead-in; target international normalized ratio: 2.0 to 3.0). Primary endpoint (intention to treat) was thrombosis, intracardiac or embolic (all events adjudicated). At 3 months and 2 years after the Fontan procedure, transthoracic and transesophageal echocardiograms were obtained as routine surveillance. Major bleeding and death were primary adverse outcomes. Results A total of 111 eligible patients were randomized (57 to ASA, 54 to heparin/warfarin). Baseline characteristics for each group were similar. There were 2 deaths unrelated to thrombosis or bleeding. There were 13 thromboses in the heparin/warfarin group (3 clinical, 10 routine echo) and 12 thromboses in the ASA group (4 clinical, 8 routine echo). Overall freedom from thrombosis 2 years after Fontan surgery was 19%, despite thrombosis prophylaxis. Cumulative risk of thrombosis was persistent but varying and similar for both groups (p = 0.45). Major bleeding occurred in 1 patient in each group. Conclusions There was no significant difference between ASA and heparin/warfarin as primary thromboprophylaxis in the first 2 years after Fontan surgery. The thrombosis rate was suboptimal for both regimens, suggesting alternative approaches should be considered. (International Multi Centre Randomized Clinical Trial Of Anticoagulation In Children Following Fontan Procedures; NCT00182104).
No takes yet. Share an insight, caveat, or question.
Monagle et al. (2011) conducted an RCT in Single-ventricle physiology post-Fontan procedure (n=111). Acetylsalicylic acid (ASA) vs. Warfarin (started within 24 h of heparin lead-in; target INR 2.0-3.0) was evaluated on Thrombosis, intracardiac or embolic (p=0.45). Acetylsalicylic acid showed no significant difference compared with heparin/warfarin for 2-year post-Fontan thrombosis.
Synapse has enriched 10 related papers. Consider them for comparative context: